Leal Therapeutics develops precision neuro-metabolic therapies for central nervous system disorders. The company's pipeline includes an ASO targeting lipid biology for ALS and an oral small molecule targeting glutamate biology for schizophrenia. These programs aim to address high-need CNS indications through novel therapeutic modalities.
Funding
$94.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
NMFounders
Product
Problem
Central nervous system (CNS) disorders like ALS, schizophrenia, and Alzheimer’s disease lack effective treatments due to the complexity of the brain and the difficulty in targeting specific disease pathways. Traditional drug development approaches often fail to address the underlying genetic and molecular mechanisms driving these conditions. This results in limited therapeutic options for patients suffering from these debilitating illnesses.
Solution
Leal Therapeutics develops precision therapeutics for CNS disorders by targeting key pathogenic pathways, such as lipid metabolism and glutamate signaling. The company utilizes antisense oligonucleotides (ASOs) and small molecules to modulate gene expression and protein activity involved in disease progression. Their lead programs focus on ALS, schizophrenia, and Alzheimer’s disease, aiming to develop disease-modifying treatments that address the root causes of these conditions. By employing a precision medicine approach, Leal Therapeutics seeks to create targeted therapies with improved efficacy and reduced side effects for patients with high unmet needs.
Target Audience
The primary target audience includes patients suffering from ALS, schizophrenia, Alzheimer’s disease, epilepsy, and other CNS disorders, as well as the physicians and healthcare providers who treat them.
Features
- Lead program LTX-002: An ASO targeting SPTLC1/lipid metabolism for ALS, peripheral neuropathy, and Alzheimer’s disease.
- Lead program LTX-001: An oral small molecule targeting GLS1/glutamate presynaptic activity for schizophrenia and MDD.
- Pipeline program LTX-003: An ASO targeting complement for Alzheimer’s disease, FTD, and AMD.
- Pipeline program LTX-004: An ASO targeting lipid trafficking for Alzheimer’s disease and Dementia with Lewy bodies.
- Pipeline program LTX-005: An ASO targeting glutamate NMDAR for refractory epilepsy and MDD/TRD.